The Venue

Les Pensières Center for Global Health

55 route d’Annecy, 74290 Veyrier-du-Lac, Annecy, France

On the shores of Lake Annecy, near the Swiss border, Les Pensières Center for Global Health is a four-hectare unspoiled haven of greenery between the lake and the mountains, where nature and construction are perfectly balanced. The historic buildings or more recent extensions, the areas for work or relaxation, the catering facilities or accommodation, all come together elegantly in this unique Savoie Alpine setting.

Les Pensières Center for Global Health, Veyrier-du-Lac, Annecy, France, the venue for ICCBH Bone School 2023 with mountains behind
The lecture theatre at Les Pensières Center for Global Health, Annecy, France, ready for ICCBH Bone School 2023
The lounge area at Les Pensières Center for Global Health, Veyrier-du-Lac, Annecy, France, the venue for ICCBH Bone School 2023

At the end of the 1950s, Dr. Charles Mérieux purchased Les Pensières as a family home. In 1967, Dr. Mérieux created the Mérieux Foundation in memory of his father, Marcel Mérieux, a student of Louis Pasteur and founder of the Institut Mérieux.

In the 1960s, the property became a place for meetings and exchange between experts from all disciplines, including researchers, biologists, doctors, vets and pharmacists. Together they shared the latest scientific advances in infectious diseases, establishing new avenues for research, as well as the best prevention strategies and ways to ensure the benefits reach those in most need. Alain Mérieux has carried on the tradition and the center organizes an increasing number of training sessions and conferences on public health issues.

The oldest buildings date back to the 16th century, when they were part of the hamlet of Les Pensières. This protected site has been classified as a historical monument since 1944. When the property was initially purchased, only the villa in the lower part of the site was renovated. The farmhouse, which still contains a wine press bearing witness to its wine-making past, was renovated in the 1980s to host the expanding number of visitors. The restaurant was added in the 1990s, as a natural extension to the meeting facilities.

Alain Mérieux continued the conversion work, creating a center that combines comfort, elegance and modernity, while preserving its natural setting. A further extension was built in 2008 in the local Savoie architectural style to house new bedrooms and additional reception areas.

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our Rare Disease division is focused on generating scientific and technological breakthroughs for people living with a rare disease via the discovery and development of integrated therapeutic solutions and novel indications of established medicines in rare and ultra-rare blood, endocrine and renal disorders. Novo Nordisk employs about 50,800 people in 80 countries out of which 3.300 within rare disease.

At Kyowa Kirin, patients are at the center of everything we do. We are a global specialty pharmaceutical company dedicated to discovering and advancing innovative medicines for rare and hard-to-treat diseases where unmet need is greatest. Based in Japan with worldwide operations, we work across the continuum—from drug discovery to commercialization—guided by our commitment to patients and their families. Backed by more than 70 years of life sciences leadership, we focus on bone and mineral disorders, hemato-oncology, and rare diseases. Rooted in collaboration, we accelerate development through partnerships with industry, academia, patients, and healthcare providers. Learn more: KyowaKirin.com

Founded in 2007, Ascendis Pharma is applying its innovative TransCon™ technology platform to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients’ lives. Guided by our core values of patients, science and passion, we use our TransCon technologies to fulfill our mission of developing new and potentially best-in-class therapies that address unmet medical needs. Ascendis is headquartered in Copenhagen, Denmark, and has additional facilities in Europe and the United States.

BridgeBio Logo

At BridgeBio, our mission is to turn beautiful science into meaningful medicines for the people who need it most. BridgeBio exists to develop transformative medicines for genetic conditions. Millions of people worldwide living with genetic conditions lack treatment options, often because drug development for small patient populations can be commercially challenging. We aim to bridge the gap between advancements in genetic science and meaningful medicines for underserved patient populations.

BioMarin is a world leader in developing and commercializing innovative therapies for rare diseases driven by genetic causes. With a 20-year history, BioMarin remains steadfast to its original mission—to bring new treatments to market that will make a big impact on small patient populations. These conditions are often inherited, difficult to diagnose, progressively debilitating, have few, if any, treatment options, and are usually ignored. Visit www.biomarin.com to learn more.

Alexion, AstraZeneca Rare Disease, is the group within AstraZeneca focused on rare diseases, created following the 2021 acquisition of Alexion Pharmaceuticals, Inc. As a leader in rare diseases for 30 years, Alexion is focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on hematology, nephrology, neurology, metabolic disorders, cardiology and ophthalmology. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries.